EDTA Chelation Therapy: How It Works, the TACT Trial, and What the Evidence Shows

EDTA chelation therapy is an intravenous infusion of edetate (ethylenediaminetetraacetic acid) that binds lead and other metals so the kidneys can excrete them, and calcium disodium EDTA is FDA approved for lead poisoning. For heart disease the evidence is mixed: the NIH-funded TACT trial (Lamas et al., JAMA 2013) reported an 18% reduction in cardiovascular events after a heart attack, but the larger confirmation trial in patients with diabetes, TACT2 (JAMA 2024), found no cardiovascular benefit even though blood lead fell by 61%.

EDTA Chelation: What It Is and How It Works

Ethylenediaminetetraacetic acid (EDTA) is a synthetic aminopolycarboxylic acid that has been used in medicine since the 1950s. Its defining property is chelation: the ability to bind metal ions and carry them out of the body through the kidneys. The word “chelation” comes from the Greek word “chele,” meaning claw, because the molecule grips a metal atom at several points at once, like a claw.

You will see the drug under several names. Edetate is the pharmacological name for EDTA. Calcium disodium EDTA (CaNa2EDTA, also called edetate calcium disodium) is the form used for lead poisoning. Disodium EDTA (Na2EDTA, edetate disodium) is the form used in the TACT trials and in most cardiovascular chelation practices. The two are not interchangeable, and confusing them has caused deaths.

EDTA chelation therapy has a long medical history in lead poisoning, and disodium EDTA was once approved for emergency treatment of hypercalcemia. Its more controversial application is for cardiovascular disease, specifically atherosclerosis, where the theory is that removing calcium and toxic metals from arterial plaques may improve blood flow and reduce cardiovascular events. That theory was largely dismissed by mainstream medicine until a landmark NIH-funded trial produced results that surprised nearly everyone, and a second trial then failed to confirm them.

Today EDTA infusions are offered mainly by integrative and functional medicine physicians, naturopathic doctors in states that allow IV therapy, and medical toxicologists for documented lead exposure. The chelation therapy treatment guide covers the wider family of chelating agents, and the national directory of chelation clinics lists practices that offer it.

The Mechanism: How EDTA Removes Metals

EDTA works through a straightforward chemical process. When infused intravenously, the EDTA molecule circulates through the bloodstream, where it encounters and binds to metal ions according to how tightly each one fits. EDTA forms stable complexes with lead, mercury, cadmium, copper, zinc, iron and other divalent and trivalent metals, and it binds calcium and magnesium as well.

Once EDTA binds a metal ion, it forms a stable, water-soluble complex called a chelate. The kidneys filter this chelate and do not reabsorb it, so it is excreted in the urine. According to the FDA label for calcium disodium EDTA, about half of a dose leaves the body within an hour and more than 95% within 24 hours. The result is a measurable drop in circulating levels of the targeted metals within hours of infusion.

This is not selective. EDTA will bind essential minerals (calcium, zinc, magnesium, iron) along with toxic metals (lead, cadmium, mercury). This is why mineral supplementation and monitoring are required during a chelation course. The therapeutic strategy relies on the fact that your body can replace essential minerals through diet and supplementation, while the toxic metals it removes do not belong there in the first place.

Calcium disodium EDTA is preloaded with calcium, so it trades its calcium for lead without pulling calcium out of the blood. Disodium EDTA carries no calcium and actively binds blood calcium, which is both the basis of the cardiovascular theory and the reason it can cause dangerous hypocalcemia when infused too fast.

IV vs. Oral EDTA

Factor	IV EDTA	Oral EDTA
Bioavailability	100% (direct bloodstream delivery)	5 to 18% absorption
Clinical evidence	TACT and TACT2 trials, decades of clinical use	Limited clinical data
Dose per session	1.5 to 3 grams (standard)	500 to 2,000 mg daily
Duration	1.5 to 3 hours per infusion	Daily oral dosing
Cost per session	$100 to $150	$30 to $60/month
Monitoring required	Yes (kidney function, minerals)	Yes, though often skipped
FDA context	Calcium disodium EDTA approved for lead; disodium EDTA studied in TACT	Not studied in major trials

The TACT Trial: The Study That Changed the Conversation

The Trial to Assess Chelation Therapy (TACT) is the single most important piece of evidence in the chelation debate. Funded by the National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH) and the National Heart, Lung, and Blood Institute, TACT was a double-blind, placebo-controlled, randomized clinical trial led by Gervasio Lamas and colleagues. It was designed to settle the question of whether EDTA chelation has any legitimate role in cardiovascular medicine.

Study Design

• Patients: 1,708 adults aged 50 and older who had experienced a prior heart attack (myocardial infarction) at least 6 weeks before enrollment.
• Treatment: 40 IV infusions of disodium EDTA (3 grams per infusion, mixed with ascorbic acid, B vitamins, magnesium, and other supplements) or matching placebo, given weekly for 30 weeks, then every 2 to 8 weeks for an additional 10 infusions.
• Primary endpoint: A composite of death from any cause, heart attack, stroke, coronary revascularization, or hospitalization for angina.
• Follow-up: Median of 55 months (approximately 4.6 years).

Results

The overall results showed a statistically significant 18% reduction in the primary composite endpoint in the EDTA chelation group compared to placebo (hazard ratio 0.82, 95% confidence interval 0.69 to 0.99, p=0.035). This means that patients who received EDTA chelation were 18% less likely to experience a major cardiovascular event during follow-up.¹

The results in the pre-specified diabetic subgroup were far more dramatic. Among the 633 diabetic participants, EDTA chelation reduced the primary endpoint by 41% (hazard ratio 0.59, 95% confidence interval 0.44 to 0.79, p<0.001). The reduction in total mortality among diabetic patients was 43%.²

Limitations and Criticisms of TACT

TACT met its primary endpoint, but the margin was narrow: the upper bound of the confidence interval was 0.99, just under the line of no effect. No single component of the composite, such as death, heart attack or stroke, was significant on its own. Many enrolling sites were chelation practices rather than academic cardiology centers, and a sizable share of participants withdrew consent before finishing, which critics argued could bias the comparison.

The diabetic result came from a subgroup. Subgroup findings, even prespecified ones, are treated as hypotheses until a dedicated trial confirms them. That is exactly why the NIH funded a second trial.

TACT2: The Follow-Up

Based on the striking results in diabetic patients, the NIH funded TACT2, a follow-up trial specifically enrolling diabetic patients with prior heart attacks. TACT2 randomized 1,000 patients at sites in the United States and Canada between 2016 and 2021 and followed the same basic protocol as the original TACT trial, 40 weekly infusions of disodium EDTA or placebo. The trial was designed to confirm or refute the dramatic benefits seen in the TACT diabetic subgroup.⁴

TACT2 refuted them. According to Lamas and colleagues in the TACT2 results published in JAMA (2024), a primary endpoint event occurred in 35.6% of the 483 chelation patients and 35.7% of the 476 placebo patients over a median of 48 months (hazard ratio 0.93, 95% confidence interval 0.76 to 1.16, p=0.53). Cardiovascular death, heart attack or stroke and all-cause death also did not differ meaningfully between groups.⁷

The infusions did what chelation chemistry predicts. Median blood lead fell from 9.03 to 3.46 micrograms per liter by the 40th infusion in the chelation group, a 61% drop, while the placebo group barely changed. The investigators concluded that despite effectively reducing blood lead levels, EDTA chelation did not reduce cardiovascular events in stable patients with diabetes and a prior heart attack.

Does EDTA Chelation Work for Heart Disease?

EDTA chelation does not reliably prevent heart attacks, strokes or cardiovascular death, based on the two largest placebo-controlled trials. TACT (2013) found a modest overall benefit in heart attack survivors, and TACT2 (2024), the trial built to confirm the strongest part of that signal, found none. Major cardiology societies have not adopted chelation as a standard therapy for coronary artery disease.

The two results together point in one direction. Lowering blood lead with EDTA is reliable, but in people already receiving modern cardiac care that reduction did not translate into fewer cardiac events. Patients with coronary disease are best served by established therapies such as statins, blood pressure control, antiplatelet drugs, cardiac rehabilitation and smoking cessation, with chelation considered, if at all, only as an informed personal choice outside the standard of care.

The evidence for other off-label uses is thinner still. Chelation has been promoted for peripheral artery disease, autism, Alzheimer disease and general detoxification, and none of these uses is supported by large randomized trials. For autism in particular, the CDC deaths described in the side effects section show what is at stake.

FDA-Approved Uses

EDTA has been FDA approved for two specific conditions, and only one approval remains in place today:

• Lead poisoning: Calcium disodium EDTA (CaNa2EDTA) is a standard treatment for symptomatic lead poisoning and lead encephalopathy in children and adults. Its FDA label covers reducing blood levels and depot stores of lead, and it notes that chelation should never replace removing the source of exposure. It is usually given in a hospital under a medical toxicologist, often together with dimercaprol (BAL) in severe cases.
• Hypercalcemia: Disodium EDTA was once used for emergency treatment of dangerously elevated calcium levels. After fatal medication errors in which disodium EDTA was given in place of calcium disodium EDTA, the FDA withdrew approval of disodium EDTA products in 2008, and other treatments for hypercalcemia are now standard.

All other uses of EDTA chelation, including cardiovascular applications, are considered off-label. Off-label does not by itself mean ineffective or illegitimate, and many widely accepted medical treatments are used off-label. For disodium EDTA, though, the situation is stricter: there is no currently approved product, so clinics that offer it for heart disease rely on compounded preparations, and the best evidence for that use (TACT2) is negative.

For people with real lead exposure, the lead poisoning treatment guide explains how blood lead testing, exposure removal and chelation fit together, and the overview of lead poisoning symptoms covers when testing is warranted.

EDTA vs. DMSA, DMPS and Other Chelating Agents

EDTA is one of several chelating agents, and each has a different profile. DMSA (succimer) is an oral drug FDA approved for lead poisoning in children, DMPS (unithiol) is used for mercury and arsenic in some countries, and dimercaprol (BAL) is an injected agent for severe lead, arsenic and mercury poisoning. Deferoxamine and deferasirox chelate iron and are used for iron overload, not heavy metals.

The choice depends on which metal is elevated, how high it is, and whether the patient can take an oral drug. The guide to oral DMSA chelation compares that option in detail, and the broader piece on heavy metal poisoning covers exposures beyond lead.

The Provoked vs. Unprovoked Urine Testing Debate

One of the most contentious issues in chelation medicine is how heavy metal levels are measured. This matters because the decision to pursue chelation therapy often hinges on test results.

Unprovoked testing measures metal levels in blood or urine without administering a chelating agent first. This reflects your body’s current circulating metal burden.

Provoked (challenge) testing involves administering a dose of a chelating agent (EDTA, DMSA, or DMPS), then collecting urine for 6 to 24 hours. The chelator pulls metals out of tissues, so provoked urine levels are always higher than unprovoked levels.

The most reliable approach is baseline unprovoked blood and urine testing, supplemented by provoked testing only when there is clinical suspicion of a significant tissue metal burden that baseline testing might miss. For more on testing options, see our guide to heavy metal testing methods.

The American College of Medical Toxicology has taken a firm position on this point: it has stated that post-challenge urine metal testing has not been validated for diagnosing metal toxicity and should not be used to decide whether someone needs chelation. For lead specifically, a venous blood lead level is the test the CDC uses to define exposure.

Standard EDTA Chelation Protocol

The protocol used in the TACT trial has become the de facto standard for cardiovascular chelation therapy, even though TACT2 later found no benefit with the same regimen. It involves:

• Pre-treatment workup: Complete metabolic panel (kidney and liver function), complete blood count, urinalysis, baseline mineral levels (calcium, magnesium, zinc, iron), and a baseline heavy metal panel.
• Infusion solution: 3 grams disodium EDTA mixed with 7 grams ascorbic acid, B vitamins (B1, B5, B6, B12), magnesium chloride, procaine (local anesthetic to reduce vein irritation), and sterile water. Total volume is approximately 500 mL.
• Infusion rate: Administered over 1.5 to 3 hours. Faster infusion increases the risk of hypocalcemia and kidney strain.
• Frequency: Weekly for the first 30 sessions, then biweekly to monthly for maintenance.
• Total course: 20 to 40 infusions for an initial course. Some patients continue with maintenance infusions monthly or quarterly.
• Monitoring: Kidney function (creatinine, BUN) checked every 5 to 10 infusions. Mineral levels checked periodically. Symptoms monitored at each visit.

In TACT the EDTA dose was adjusted downward for reduced kidney function, which is standard practice. Lead poisoning protocols with calcium disodium EDTA are different: they are dosed by body size, usually run over a few days in a hospital, and are paired with repeat blood lead testing rather than a fixed number of weekly sessions.

What to Expect During an EDTA Infusion

1. The clinician reviews your recent labs, especially kidney function and calcium, and checks blood pressure before starting.
2. An IV line is placed in a forearm vein, ideally a larger one to limit burning at the site.
3. The EDTA solution runs slowly over 1.5 to 3 hours while you sit in a reclining chair, and staff check on you during the drip.
4. You report any tingling around the mouth or fingers, muscle cramps or palpitations right away, because these can signal low calcium.
5. After the infusion you rest for 15 to 30 minutes before standing, then drink fluids and eat normally for the rest of the day.
6. Labs are repeated every 5 to 10 sessions, and the course is paused if creatinine rises or minerals fall.

Side Effects and Risks

Common Side Effects

• Burning or discomfort at the IV site: The most frequent complaint. Adding procaine to the infusion solution and using a larger vein reduces this.
• Fatigue: Many patients feel tired for 12 to 24 hours after infusion. This typically improves as the body adjusts over the first few sessions.
• Headache: Mild headache is common, especially in the first few sessions. Adequate hydration before and after infusion helps.
• Nausea: Occasional, usually mild. Eating a light meal before infusion reduces this.
• Temporary drop in blood pressure: EDTA can cause mild vasodilation. Patients should sit for 15 to 30 minutes after infusion before standing.

Serious Risks

In the TACT trial, the safety profile was reassuring. Serious adverse events were similar between the chelation and placebo groups. When EDTA chelation is administered at proper doses, at appropriate infusion rates, with adequate monitoring by trained staff, serious harm is uncommon, but the margin for error is small.

Outside trials, errors have been fatal. The CDC reported in its 2006 MMWR report on deaths from chelation-related hypocalcemia that three people in Texas, Pennsylvania and Oregon died of cardiac arrest during chelation between 2003 and 2005. Two were children who received disodium EDTA instead of calcium disodium EDTA, one of them a 5-year-old boy with autism. The CDC advised that children should never receive disodium EDTA.⁸ The guide to side effects of chelation therapy goes further into symptoms and monitoring.

Who Should Avoid EDTA Chelation?

EDTA chelation is a poor fit for people with significant kidney impairment, because the kidneys clear both the drug and the metals it carries. It is also generally avoided in pregnancy, in people with low calcium or uncorrected low magnesium, in severe heart failure where the fluid volume of each infusion is a concern, and in people with certain blood disorders or a history of reactions to EDTA.

Children should receive chelation only for documented lead poisoning, only with calcium disodium EDTA or another approved agent, and only under a pediatric or medical toxicology team. People taking digoxin, insulin or other drugs affected by calcium, potassium or glucose shifts need their prescribing physician involved before any course starts.

Cost and Insurance

Cost Component	Typical Range
Individual IV infusion	$100 to $150
Initial workup (labs, consultation)	$200 to $500
20-infusion course	$2,000 to $3,000
40-infusion course (TACT protocol)	$4,000 to $6,000
Ongoing monitoring labs	$50 to $200 per draw
Monthly maintenance infusion	$100 to $150

Insurance rarely covers EDTA chelation for cardiovascular indications. It is typically covered for lead poisoning when ordered by a toxicologist. HSA and FSA accounts can generally be used for chelation therapy when prescribed by a licensed provider for a diagnosed medical condition.

Prices vary by region and by what each clinic bundles into a session, so ask for a written quote that lists the infusion, the labs and the consultation separately. After TACT2, it is reasonable to ask a clinic how it explains that trial before you commit to a full course.

Finding a Qualified Provider

If you are considering EDTA chelation, choosing the right provider is critical. Look for:

• Training and certification: The American College for Advancement in Medicine (ACAM) offers training in chelation therapy. Board certification in integrative medicine, functional medicine, or toxicology provides relevant background.
• Proper monitoring protocols: Any provider who skips baseline labs or does not monitor kidney function during treatment is cutting corners.
• Evidence-based discussion: A good provider will discuss both TACT and TACT2 honestly, including the negative TACT2 result, and will not promise that chelation will reverse or eliminate heart disease.
• Appropriate patient selection: Chelation is not for everyone. Patients with significant kidney impairment, severe heart failure, or certain blood disorders may not be appropriate candidates.

For suspected lead poisoning, the right first contact is usually a primary care physician or a medical toxicologist through a poison control center, not a cash-pay infusion clinic. For other questions, you can browse chelation therapy clinics across the US or open a state list such as chelation providers in Florida or chelation providers in New York, then check each practice against the points above.

Listing order in the directory is not paid ranking, and Featured slots are clearly labeled and capped. A Verified label means the clinic completed credential checks, not that it spent more. Regenerated.com is free for patients, and inclusion in the directory is not an endorsement; how Featured, Verified and organic listings differ explains each label.

Frequently Asked Questions

Does EDTA chelation clear clogged arteries?

EDTA chelation has not been shown to clear clogged arteries or reliably prevent heart attacks. The original TACT trial (2013) found 18% fewer cardiovascular events in heart attack survivors, but the larger confirmation trial in patients with diabetes, TACT2 (JAMA, 2024), found no reduction in events with the same 40-infusion regimen. Imaging studies showing plaque removal are lacking, and cardiology guidelines still rely on statins, blood pressure control and procedures such as stents or bypass.

What is EDTA chelation FDA approved for?

Calcium disodium EDTA is FDA approved for lead poisoning and lead encephalopathy in children and adults. It lowers blood lead and lead stored in tissues and is usually given in a hospital under a medical toxicologist. Disodium EDTA, the form used for heart disease, was once approved for emergency hypercalcemia, but the FDA withdrew its approval in 2008 after fatal mix-ups, so cardiovascular chelation today is off-label and relies on compounded products.

How many EDTA chelation sessions are typical?

Cardiovascular chelation courses modeled on TACT typically run 20 to 40 infusions, given weekly at first and then every few weeks, with each session lasting 1.5 to 3 hours. TACT and TACT2 both used 40 infusions. Lead poisoning treatment with calcium disodium EDTA works differently: it is dosed by body size over a few days and repeated only if blood lead stays high. Your clinician should set the course length from labs, not a package.

Is EDTA chelation therapy safe?

EDTA chelation carries real but manageable risks when trained staff run infusions slowly and monitor labs. In TACT, serious adverse events were similar with chelation and placebo. The main dangers are hypocalcemia, kidney strain and mineral depletion. The CDC (2006) linked three deaths to chelation-related hypocalcemia, two in children given disodium EDTA instead of calcium disodium EDTA. People with kidney disease, low calcium, pregnancy or severe heart failure are generally poor candidates.

How much does EDTA chelation cost, and does insurance cover it?

A single EDTA infusion typically costs $100 to $150, and a full course of 20 to 40 infusions runs about $2,000 to $6,000 before labs and consultation fees. Insurance rarely covers chelation for heart disease because it is off-label and TACT2 found no benefit. Coverage is generally limited to documented lead poisoning ordered by a toxicologist. HSA and FSA funds can often be used when a licensed provider prescribes chelation for a diagnosed condition.

Is oral EDTA as effective as IV chelation?

Oral EDTA is not an equivalent to IV chelation, because only about 5 to 18% of an oral dose is absorbed. Both TACT trials used intravenous disodium EDTA, and no large trial has tested oral EDTA for heart disease or heavy metal toxicity. For documented lead poisoning in children, the oral agent clinicians use is DMSA (succimer), which is FDA approved for that purpose, rather than an over-the-counter EDTA supplement.

The Bottom Line

EDTA chelation therapy sits at an interesting intersection of established science and contested evidence. Its mechanism is well understood, calcium disodium EDTA is an approved treatment for lead poisoning, and the TACT trial provided the first rigorous signal that it might have a role in cardiovascular medicine, particularly for diabetic patients with prior heart attacks.

That signal did not hold up. It is not a substitute for established cardiovascular therapies (statins, blood pressure medications, lifestyle modification), and TACT2, the 2024 trial built to confirm the diabetic benefit, found no reduction in cardiovascular events despite a 61% fall in blood lead. For patients who have had a heart attack, the strongest evidence now says chelation adds cost and monitoring without a measurable cardiac benefit, while for documented lead poisoning it remains a recognized medical treatment.

For a broader look at chelation therapy options and when they make sense, visit our chelation therapy guide. For more on potential side effects, see our article on chelation therapy side effects.

Sources

1. Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241-1250. doi:10.1001/jama.2013.2107 ↩
2. Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014;7(1):15-24. doi:10.1161/CIRCOUTCOMES.113.000663 ↩
3. Lamas GA, Boineau R, Goertz C, et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: the factorial group results of the Trial to Assess Chelation Therapy. Am Heart J. 2014;168(1):37-44.e5. doi:10.1016/j.ahj.2014.02.012 ↩
4. Lamas GA, Anstrom KJ, Aviles RJ, et al. The Trial to Assess Chelation Therapy 2 (TACT2): rationale and design. Am Heart J. 2022;252:1-11. doi:10.1016/j.ahj.2022.05.013 ↩
5. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010;7(7):2745-2788. doi:10.3390/ijerph7072745
6. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease: a systematic review. Environ Health Perspect. 2007;115(3):472-482. doi:10.1289/ehp.9785
7. Lamas GA, Anstrom KJ, Navas-Acien A, et al. Edetate disodium-based chelation for patients with a previous myocardial infarction and diabetes: TACT2 randomized clinical trial. JAMA. 2024;332(10):794-803. doi:10.1001/jama.2024.11463 PubMed 39141382 ↩
8. Centers for Disease Control and Prevention. Deaths associated with hypocalcemia from chelation therapy: Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep. 2006;55(8):204-207. CDC MMWR ↩

Related Reading

• Chelation Therapy: The Complete Guide
• Chelation Therapy Side Effects: What to Know
• Heavy Metal Testing: Comparing Your Options
• DMSA Chelation: How It Works and When It Is Used
• Regenerative Medicine for Longevity